Alwin D R Huitema
Overview
Explore the profile of Alwin D R Huitema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
394
Citations
4784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meertens M, Rosing H, Steeghs N, Beijnen J, Huitema A
Biomed Chromatogr
. 2025 Mar;
39(5):e70056.
PMID: 40084678
Home-sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital-based sampling methods, though it presents challenges. This review aims to summarize the...
2.
Lin L, Lucassen M, van der Noort V, Egberts T, Beijnen J, Huitema A
Drug Discov Today
. 2025 Mar;
30(3):104324.
PMID: 40054765
Before real world data (RWD)-derived external control arms (ECAs) can be applied in clinical trials within the field of oncology, it must be determined whether these ECAs can function as...
3.
Meertens M, Kerssemakers N, de Vries N, Rosing H, Steeghs N, Beijnen J, et al.
Ther Drug Monit
. 2025 Feb;
PMID: 39996568
Background: Therapeutic Drug Monitoring optimizes oral anticancer drug treatment by measuring plasma levels. Volumetric absorptive microsampling (VAMS) allows home sampling with a minimal blood sample. However, methods for converting whole...
4.
Admiraal R, Nierkens S, Bierings M, Belderbos M, Huitema A, Bredius R, et al.
Blood Adv
. 2025 Feb;
PMID: 39983052
Anti-thymocyte globulin (ATG) is used in pediatric allogeneic hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure (GF). Poor or delayed T-cell recovery, associated with increased mortality, is...
5.
van der Kleij M, Meertens M, Groenland S, Kordes S, Bergman A, de Feijter J, et al.
Br J Cancer
. 2025 Feb;
PMID: 39934337
Background: Previous studies demonstrated better outcomes for mCRPC (metastatic castration resistant prostate cancer) patients with higher abiraterone exposure (minimal plasma concentration (C) > 8.4 ng/mL), but around 40% of patients...
6.
Overbeek J, van Erp N, Burger D, den Broeder A, Koolen S, Huitema A, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39909979
Objectives: Pharmacokinetic (PK) boosting is the intentional use of strong inhibitors of metabolic enzymes or transporters to boost the systemic exposure of a therapeutic drug. PK boosting is expanding to...
7.
Meertens M, Giraud E, Hassan E, Zielhuis S, Snels T, Desar I, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):25.
PMID: 39820703
Purpose: After initial approval of lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), it has also shown promising outcomes in among others metastatic renal cell carcinoma (mRCC). Given that trial populations...
8.
Heersche N, Lanser D, Muntinghe-Wagenaar M, Mohmaed Ali M, Ulas E, Trooster T, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39617342
Introduction: Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for ALK-positive (ALK+) NSCLC. Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity....
9.
Schouten W, Van Bocxlaer K, Rosing H, Huitema A, Beijnen J, Kratz J, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 Nov;
1250:124377.
PMID: 39577310
DNDI-6148 is a promising new oral drug for the treatment of cutaneous leishmaniasis (CL), a parasitic neglected tropical disease that affects impoverished populations worldwide. Preclinical target site pharmacokinetics (PK) studies...
10.
Mohmaed Ali M, Nijstad A, Boosman R, Crombag M, Barnett S, Veal G, et al.
Clin Pharmacokinet
. 2024 Nov;
63(12):1711-1722.
PMID: 39549227
Background: The effect of age on doxorubicin pharmacokinetics remains inconclusive, especially in patients at the extremes of the age spectrum. We developed a population pharmacokinetic model to further investigate the...